Conferences - Results from #240

ESMO 2021: Estimation of Overall Survival With Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study September 18, 2021

ESMO 2021: Randomized, Open-Label, 3-Arm Phase 3 Study Comparing MK-1308A + Lenvatinib and Pembrolizumab + Belzutifan + Lenvatinib versus Pembrolizumab + Lenvatinib as First-line Treatment for Advanced Clear Cell RCC September 18, 2021

ESMO 2021: Pembrolizumab Plus Olaparib in Patients with Docetaxel-Pretreated mCRPC: Update of KEYNOTE-365 Cohort A with a Minimum of 11 Months of Follow-Up for all Patients September 18, 2021

ESMO 2021: Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial Identify Therapy Resistance September 18, 2021

ESMO 2021: Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer Patients in the US September 18, 2021

ESMO 2021: Conditional Survival and 5-Year Follow-Up in CheckMate 214: First-Line Nivolumab + Ipilimumab Versus Sunitinib in Advanced RCC September 18, 2021

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and SBRT to the Prostate in Men with Newly Diagnosed mHSPC September 18, 2021

ESMO 2021: A Discussion on the Results of the GETUG/AFU VESPER V05 Phase III Trial and on Pembrolizumab in Combination with sEphB4-HSA (B4) in a Phase II Trial for Previously Treated Metastatic Urothelial Carcinoma September 18, 2021

ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC) September 18, 2021

ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC September 18, 2021

ESMO 2021: Apalutamide for Advanced Prostate Cancer in Older Patients: Combined Analysis of TITAN & SPARTAN September 18, 2021

ESMO 2021: Pembrolizumab Monotherapy for Docetaxel-Pretreated mCRPC: Updated Analyses with 4 Years of Follow-up from Cohorts 1-3 of the KEYNOTE-199 Study September 17, 2021

ESMO 2021: Time Course Profile of Adverse Events of Interest and Serious Adverse Events with Darolutamide in the ARAMIS Trial September 17, 2021

ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib versus Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer September 17, 2021

ESMO 2021: Patient-Reported Outcomes in Prostate Cancer Patients Receiving PSMA-Targeted Radionuclide Therapy September 17, 2021

ESMO 2021: IMvigor011: A Global, Double-Blind, Randomized Phase 3 Study of Atezolizumab Versus Placebo As Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Post Cystectomy September 17, 2021

ESMO 2021: MicroRNA in the Management of Testicular Cancer September 17, 2021

ESMO 2021: Systemic Treatments and Novel Approaches September 17, 2021

ESMO 2021: Treatment Patterns and Overall Survival in Metastatic Castration-Sensitive Prostate Cancer from 2006 to 2019 September 17, 2021

ESMO 2021: The Phase 2 NORSE Trial Discussion: A Novel Combination in the First-Line Setting for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and FGFR Alterations September 17, 2021

Page 13 of 432

email news signup